Panachan Jirawan, Rojsirikulchai Napat, Pongsakul Nutkridta, Khowawisetsut Ladawan, Pongphitcha Pongpak, Siriboonpiputtana Teerapong, Chareonsirisuthigul Takol, Phornsarayuth Pitichai, Klinkulab Nisakorn, Jinawath Natini, Chiangjong Wararat, Anurathapan Usanarat, Pattanapanyasat Kovit, Hongeng Suradej, Chutipongtanate Somchai
Department of Pediatrics, Division of Hematology and Oncology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
Cancers (Basel). 2022 May 26;14(11):2627. doi: 10.3390/cancers14112627.
amplification is the strongest predictor of high-risk neuroblastoma (NB). The standard procedure to detect status requires invasive procedures. Extracellular vesicles (EVs) contain molecular signatures of originated cells, present in biofluids, and serve as an invaluable source for cancer liquid biopsies. This study aimed to establish an EV-based method to detect the status of NB. Two EV subtypes, i.e., microvesicles (MVs) and exosomes, were sequentially isolated from the culture supernatant by step-wise centrifugation, ultrafiltration, and size-exclusion chromatography. Quantitative RT-PCR was performed to detect mRNA. As a result, mRNA was detectable in the MVs, but not exosomes, of -amplified NB cells. mRNA-containing MVs (-MV) were successfully detected in three distinct -amplified NB cell lines but absent in three non-amplification cells. The simulated samples were prepared by pulsing MVs into human serum. -MV detection in the simulated samples showed a less interfering effect from the human blood matrix. Validation using clinical specimens (2 mL bone marrow plasma) obtained from patients at various disease stages showed a promising result. Five out of six specimens of -amplified patients showed positive results, while there were no false positives in four plasma samples of the MYCN non-amplification group. This study communicated a novel EV-based method for detecting the status of pediatric NB based on mRNA contents in MVs. Future studies should be pursued in a prospective cohort to determine its true diagnostic performance.
扩增是高危神经母细胞瘤(NB)最强的预测指标。检测[具体基因名称]状态的标准程序需要侵入性操作。细胞外囊泡(EVs)包含起源细胞的分子特征,存在于生物流体中,是癌症液体活检的宝贵来源。本研究旨在建立一种基于EVs的方法来检测NB的[具体基因名称]状态。通过逐步离心、超滤和尺寸排阻色谱法,从培养上清液中依次分离出两种EV亚型,即微囊泡(MVs)和外泌体。进行定量逆转录聚合酶链反应(qRT-PCR)以检测[具体基因名称]mRNA。结果,在[具体基因名称]扩增的NB细胞的MVs中可检测到[具体基因名称]mRNA,但在外泌体中未检测到。在三种不同的[具体基因名称]扩增的NB细胞系中成功检测到含[具体基因名称]mRNA的MVs([具体基因名称]-MV),但在三种[具体基因名称]非扩增细胞中未检测到。通过将MVs注入人血清制备模拟样本。模拟样本中[具体基因名称]-MV检测显示来自人血基质的干扰作用较小。使用从处于不同疾病阶段的患者获得的临床标本(2 mL骨髓血浆)进行验证显示出有希望的结果。[具体基因名称]扩增患者的六个标本中有五个显示阳性结果,而[具体基因名称]非扩增组的四个血浆样本中没有假阳性。本研究传达了一种基于EVs的新方法,用于根据MVs中[具体基因名称]mRNA含量检测小儿NB的[具体基因名称]状态。未来应在前瞻性队列中进行研究以确定其真正的诊断性能。